SCHEMBL5113192

SCHEMBL5113192

CCN1C(=O)Cc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 12/20 0.53
NOTUM Q6P988 1/20 0.51
HTR1A P08908 4/20 0.50
HPGD P15428 1/20 0.50
DRD2 P14416 3/20 0.49
DRD5 P21918 2/20 0.49
DRD3 P35462 2/20 0.49
BRD4 O60885 1/20 0.49
DRD4 P21917 1/20 0.48
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
ATAD2 Q6PL18 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30382092 1.00 HTR7 (0.53) HTR7NOTUMHTR1AHPGDDRD2
Hydrochloric Acid SCHEMBL29877918 0.98 HTR7 (0.51) HTR7NOTUMHTR1AHPGDDRD2
SCHEMBL25162957 0.98 HPGD (0.53) HTR7NOTUMHTR1AHPGDDRD2
SCHEMBL5507788 0.86 CES1 (0.53) ALDH1A1
SCHEMBL8240109 0.85 HTR7 (0.57) HTR7NOTUMHTR1ADRD2DRD5
SCHEMBL9095440 0.84 HDAC3 (0.44) HTR7NOTUMHTR1ADRD2DRD5
SCHEMBL29525493 0.83 POLB (0.65) DRD2DRD3DRD4ATAD2
SCHEMBL8556193 0.83 POLB (0.65) DRD2DRD3DRD4ATAD2
SCHEMBL7476444 0.82 DRD2 (0.63) HTR7HTR1ADRD2DRD5DRD3
SCHEMBL5506721 0.82 GAA (0.51) HTR7HPGDBRD4ATAD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768781-A Method for synthesizing quaternary carbon o-diamine by photocatalysis 大连理工大学 2023-09-19 CN claimed
WO-2024059665-A1 DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
CN-116768781-A Method for synthesizing quaternary carbon o-diamine by photocatalysis 大连理工大学 2023-09-19 CN disclosed
CN-111333660-B 550nm excited rhodamine dye and preparation method thereof 中国科学院大连化学物理研究所 2022-03-18 CN disclosed
CN-108658835-B Method for synthesizing indole-2-ketone compound 中国科学院成都有机化学有限公司 2021-12-03 CN disclosed
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2021-05-06 US disclosed
CN-112088157-A Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors 拉文纳制药公司 2020-12-15 CN disclosed
CN-111334079-A Full-spectrum high-brightness and high-stability fluorescent dye and synthesis and application thereof 中国科学院大连化学物理研究所 2020-06-26 CN disclosed
US-4831031-A Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity PFIZER INC. (US) 1989-05-16 US disclosed
US-4810801-A Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases BOEHRINGER MANNHEIM GMBH (DE) 1989-03-07 US disclosed
EP-0281309-A1 Piperazinyl-heterocyclic compounds PFIZER INC. (US) 1988-09-07 EP disclosed
US-4686224-A Oxindole antiinflammatory agents PFIZER INC. (US) 1987-08-11 US disclosed
US-4644005-A ANTIARTHRITIC AGENTS PFIZER INC. (US) 1987-02-17 US disclosed
EP-0181136-A2 Oxindole antiinflammatory agents PFIZER INC. (US) 1986-05-14 EP disclosed
EP-0048834-A1 Method for measurement of trace enzymes FUJI PHOTO FILM CO., LTD. (JP) 1982-04-07 EP disclosed
US-4160032-A Oxindoles as sleep-inducers SANDOZ, INC. (US) 1979-07-03 US disclosed
US-4051099-A ISOINDOLES CIBA-GEIGY CORPORATION (US) 1977-09-27 US disclosed
US-3961952-A ELECTROPHOTOGRAPHY, SUPPORTS, COATINGS ITEK CORPORATION (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL HTR7 4171/4885NOTUM 3025/4885HTR1A 2664/4885
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 HTR7 4074/4885NOTUM 3861/4885HTR1A 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.